Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEPHROS INCNEPH · Entity 7279 | CEO Specialty Renal Products | May 24, 2021 | June 01, 2021 |
| Rezolute, Inc.RZLT · Entity 1990 | CFO | July 02, 2026 | July 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEPHROS INC
Report date May 24, 2021 · Filed June 01, 2021 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy UTMA #1 | 8,947 |
Reported balance
After 2021-05-27 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2021-05-27 · Tax withholding · Disposed 349 · Balance 8,947 |
| Common StockSEC Table I · non-derivative | IndirectBy UTMA #2 | 8,669 |
Reported balance
After 2021-05-27 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2021-05-27 · Tax withholding · Disposed 349 · Balance 8,669 |
Rezolute, Inc.
Report date July 02, 2026 · Filed July 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 411,400 |
Reported balance
After 2026-07-02 transaction · row 1
1 source rowRow 1 · 2026-07-02 · Tax withholding · Disposed 3,062 · Balance 411,400 F1: The disposition reported on this Form 4 represents shares disposed of by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The disposition is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. |
| Common SharesSEC Table I · non-derivative | IndirectHeld by minor child #2 | 7,000 |
Reported balance
Holding disclosure · report date 2026-07-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 7,000 |
| Common SharesSEC Table I · non-derivative | IndirectHeld by minor child #3 | 7,000 |
Reported balance
Holding disclosure · report date 2026-07-02 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 7,000 |
| Common SharesSEC Table I · non-derivative | IndirectHeld by PoC Capital LLC | 40,000 |
Reported balance
Holding disclosure · report date 2026-07-02 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 40,000 F2: PoC Capital, LLC is a California limited liability company managed by the reporting person. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
| Common SharesSEC Table I · non-derivative | IndirectHeld by spouse | 20,000 |
Reported balance
Holding disclosure · report date 2026-07-02 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 20,000 |
| Common SharesSEC Table I · non-derivative | IndirectHeld by minor child #1 | 23,000 |
Reported balance
Holding disclosure · report date 2026-07-02 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 23,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The disposition reported on this Form 4 represents shares disposed of by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The disposition is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F2: PoC Capital, LLC is a California limited liability company managed by the reporting person. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 02, 2026 Filed Jul 7, 2026 21:26 UTC | Rezolute, Inc. RZLT · Entity 1990 | Tax withholdingCommon Shares | 3,062 | $4.99 | $15,279.38 |
DisclosureSEC source: 0000912282-26-000929 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 411,400 F1 · kind: The disposition reported on this Form 4 represents shares disposed of by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The disposition is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 30, 2026 Filed Mar 31, 2026 20:59 UTC | Rezolute, Inc. RZLT · Entity 1990 | PurchaseCommon Shares | 10,000 | $2.85 | $28,500.00 |
DisclosureSEC source: 0000912282-26-000533 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 414,462 Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 23:16 UTC | Rezolute, Inc. RZLT · Entity 1990 | Tax withholdingCommon Shares | 11,438 | $2.99 | $34,199.62 |
DisclosureSEC source: 0000912282-26-000411 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 404,462 F1 · kind: The disposition reported on this Form 4 represents shares disposed of by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The disposition is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The sale price reported above is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.98 to $3.07, inclusive. The reporting person undertakes to provide to Rezolute, Inc., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 00:35 UTC | Rezolute, Inc. RZLT · Entity 1990 | PurchaseCommon Shares | 2,500 | $1.79 | $4,475.00 |
DisclosureSEC source: 0000912282-25-001424 · form4.xml · nonDerivative · entry 3 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Indirect · Held by minor child #3 Disclosed balance after: 7,000 Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 00:35 UTC | Rezolute, Inc. RZLT · Entity 1990 | PurchaseCommon Shares | 2,500 | $1.79 | $4,462.50 |
DisclosureSEC source: 0000912282-25-001424 · form4.xml · nonDerivative · entry 2 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Indirect · Held by minor child #2 Disclosed balance after: 7,000 F2 · price: The purchase price reported above is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.78 to $1.79, inclusive. The reporting person undertakes to provide to Rezolute, Inc., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 00:35 UTC | Rezolute, Inc. RZLT · Entity 1990 | PurchaseCommon Shares | 40,000 | $1.77 | $70,640.00 |
DisclosureSEC source: 0000912282-25-001424 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 415,900 F1 · price: The purchase price reported above is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.65 to $1.81, inclusive. The reporting person undertakes to provide to Rezolute, Inc., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 09, 2025 Filed Dec 10, 2024 14:11 UTC | Rezolute, Inc. RZLT · Entity 1990 | PurchaseCommon Shares | 10,549 | $5.04 | $53,166.96 |
DisclosureSEC source: 0000912282-24-000863 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,900 F1 · price: The purchase price reported above is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.985 to $5.0559, inclusive. The reporting person undertakes to provide to Rezolute, Inc., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 22:31 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantEmployee Stock Option (Right to Buy) · Derivative | 63,000 | $0.00 Strike: $10.16 | $0.00 |
DisclosureSEC source: 0000912282-25-001292 · form4.xml · derivative · entry 7 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,000 Underlying: Common Shares · 63,000 shares Expires 2035-11-19 F3 · derivative.exercise_date: The options vest 1/36th monthly beginning on December 19, 2025. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 22:31 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantCommon Shares | 107,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-001292 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,900 F1 · shares: Represents grant of restricted stock units which vest annually over a three-year period with the first RSUs vesting on December 1, 2026. Read SEC document |
| June 24, 2025 Filed Jun 24, 2025 16:41 UTC | Rezolute, Inc. RZLT · Entity 1990 | PurchaseCommon Shares | 5,000 | $4.05 | $20,250.00 |
DisclosureSEC source: 0000912282-25-000706 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 268,900 Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 01:29 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.39 | $0.00 |
DisclosureSEC source: 0000912282-25-000661 · form4.xml · derivative · entry 7 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2035-06-10 F3 · derivative.exercise_date: The options vest as follows: 1/36th monthly beginning on July 10, 2025. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 01:29 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantCommon Shares | 26,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000661 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 263,900 F1 · shares: Represents grant of restricted stock units which vest as follows: 1/3 on July 1, 2026; 1/3 on July 1, 2027; and 1/3 on July 1, 2028. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 12:40 UTC | Rezolute, Inc. RZLT · Entity 1990 | PurchaseCommon Shares | 10,000 | $2.88 | $28,800.00 |
DisclosureSEC source: 0000912282-25-000339 · form4.xml · nonDerivative · entry 2 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Indirect · Minor child #1 Disclosed balance after: 23,000 Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 12:40 UTC | Rezolute, Inc. RZLT · Entity 1990 | PurchaseCommon Shares | 10,000 | $2.89 | $28,900.00 |
DisclosureSEC source: 0000912282-25-000339 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 237,900 Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 02:29 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantEmployee Stock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $4.61 | $0.00 |
DisclosureSEC source: 0000912282-25-000180 · form4.xml · derivative · entry 7 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Shares · 45,000 shares Expires 2035-02-16 F3 · derivative.exercise_date: The options vest as follows: 1/36th monthly beginning on March 16, 2025. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 02:29 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantCommon Shares | 77,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000180 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 227,900 F1 · shares: Represents grant of restricted stock units which vest as follows: 1/3 on March 1, 2026; 1/3 on March 1, 2027; and 1/3 on March 1, 2028. Read SEC document |
| December 18, 2024 Filed Dec 18, 2024 23:01 UTC | Rezolute, Inc. RZLT · Entity 1990 | PurchaseCommon Shares | 10,000 | $4.29 | $42,900.00 |
DisclosureSEC source: 0000912282-24-000908 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,900 F1 · price: The purchase price reported above is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.275 and $4.33, inclusive. The reporting person undertakes to provide to Rezolute, Inc., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 12, 2024 Filed Dec 12, 2024 21:54 UTC | Rezolute, Inc. RZLT · Entity 1990 | PurchaseCommon Shares | 9,000 | $4.60 | $41,400.00 |
DisclosureSEC source: 0000912282-24-000884 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,900 Read SEC document |
| September 23, 2024 Filed Sep 24, 2024 17:03 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $4.79 | $0.00 |
DisclosureSEC source: 0000912282-24-000673 · form4.xml · derivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Shares · 100,000 shares Expires 2034-09-23 F1 · derivative.exercise_date: The options vest as follows: One-fourth (1/4) on the one-year anniversary of the grant date and one thirty-sixth (1/36) of the remaining options shall vest on the same day of each month thereafter until the option is 100% vested. The unvested portion of the option will not be exercisable on or after the Reporting Person's termination of Continuous Service subject to the terms of the Reporting Person's employment agreement. Read SEC document |
| June 14, 2024 Filed Jun 14, 2024 16:06 UTC | Rezolute, Inc. RZLT · Entity 1990 | PurchaseCommon Shares | 40,000 | $4.04 | $161,568.00 |
DisclosureSEC source: 0000912282-24-000494 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Indirect · Held by PoC Capital, LLC Disclosed balance after: 40,000 F1 · price: The purchase price reported above is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.85 to $4.25, inclusive. The reporting person undertakes to provide to Rezolute, Inc., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F2 · ownership.nature: PoC Capital, LLC is a California limited liability company managed by the reporting person. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 29, 2024 Filed May 31, 2024 20:05 UTC | Rezolute, Inc. RZLT · Entity 1990 | PurchaseCommon Shares | 451 | $3.50 | $1,578.50 |
DisclosureSEC source: 0000912282-24-000472 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,351 Read SEC document |
| May 24, 2024 Filed May 28, 2024 18:48 UTC | Rezolute, Inc. RZLT · Entity 1990 | PurchaseCommon Shares | 2,942 | $3.23 | $9,502.66 |
DisclosureSEC source: 0000912282-24-000460 · form4.xml · nonDerivative · entry 2 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Indirect · Held by minor child #1 Disclosed balance after: 13,000 F1 · price: The purchase price reported above is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.21 to $3.23, inclusive. The reporting person undertakes to provide to Rezolute, Inc., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 23, 2024 Filed May 28, 2024 18:48 UTC | Rezolute, Inc. RZLT · Entity 1990 | PurchaseCommon Shares | 58 | $2.85 | $165.30 |
DisclosureSEC source: 0000912282-24-000460 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Indirect · Held by minor child #1 Disclosed balance after: 10,058 Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 13:17 UTC | Rezolute, Inc. RZLT · Entity 1990 | PurchaseCommon Shares | 20,000 | $1.69 | $33,830.00 |
DisclosureSEC source: 0000912282-24-000274 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Indirect · Held by spouse Disclosed balance after: 20,000 F1 · price: The purchase price reported above is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.69 to $1.70, inclusive. The reporting person undertakes to provide to Rezolute, Inc., any securityholder of Rezolute, Inc. or the staff of the Securities an Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 08, 2024 Filed Mar 8, 2024 17:37 UTC | Rezolute, Inc. RZLT · Entity 1990 | PurchaseCommon Shares | 50,000 | $1.93 | $96,345.00 |
DisclosureSEC source: 0000912282-24-000232 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,900 F1 · price: The purchase price reported above is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.83 to $1.95, inclusive. The reporting person undertakes to provide to Rezolute, Inc., any securityholder of Rezolute, Inc. or the staff of the Securities an Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 12:01 UTC | Rezolute, Inc. RZLT · Entity 1990 | PurchaseCommon Shares | 4,500 | $1.37 | $6,165.00 |
DisclosureSEC source: 0000912282-24-000163 · form4.xml · nonDerivative · entry 3 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Indirect · Held by minor child #3 Disclosed balance after: 4,500 Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 12:01 UTC | Rezolute, Inc. RZLT · Entity 1990 | PurchaseCommon Shares | 4,500 | $1.37 | $6,165.00 |
DisclosureSEC source: 0000912282-24-000163 · form4.xml · nonDerivative · entry 2 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Indirect · Held by minor child #2 Disclosed balance after: 4,500 Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 12:01 UTC | Rezolute, Inc. RZLT · Entity 1990 | PurchaseCommon Shares | 41,900 | $1.30 | $54,411.34 |
DisclosureSEC source: 0000912282-24-000163 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,900 F1 · price: The purchase price reported above is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.17 to $1.39, inclusive. The reporting person undertakes to provide to Rezolute, Inc.., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 17:47 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantEmployee Stock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0000912282-24-000089 · form4.xml · derivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Shares · 275,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: The options were granted on January 23, 2024, and shall vest as follows: One-fourth (1/4) on the one-year anniversary of the grant date and one thirty-sixth (1/36) of the remaining options shall vest on the same day of each month thereafter until the option is 100% vested. The unvested portion of the option will not be exercisable on or after the Reporting Person's termination of Continuous Service subject to the terms of the Reporting Person's employment agreement. Read SEC document |
| May 27, 2021 Filed Jun 1, 2021 21:39 UTC Amendment | NEPHROS INC NEPH · Entity 7279 | Tax withholdingCommon Stock | 349 | $2.70 | $942.30 |
DisclosureSEC source: 0000914190-21-000169 · edgar.xml · nonDerivative · entry 2 Evans Daron · CIK 0001411726 · CEO Specialty Renal Products 10b5-1 filing: Not disclosed Ownership: Indirect · By UTMA #2 Disclosed balance after: 8,669 Read SEC document |
| May 27, 2021 Filed Jun 1, 2021 21:39 UTC Amendment | NEPHROS INC NEPH · Entity 7279 | Tax withholdingCommon Stock | 349 | $2.70 | $942.30 |
DisclosureSEC source: 0000914190-21-000169 · edgar.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CEO Specialty Renal Products 10b5-1 filing: Not disclosed Ownership: Indirect · By UTMA #1 Disclosed balance after: 8,947 Read SEC document |
| May 24, 2021 Filed May 25, 2021 19:40 UTC | NEPHROS INC NEPH · Entity 7279 | OtherCommon Stock Warrants (Right to Buy) · Derivative | 1,111 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0000914190-21-000162 · edgar.xml · derivative · entry 12 Evans Daron · CIK 0001411726 · CEO of Specialty Renal Product 10b5-1 filing: Not disclosed Ownership: Indirect · By UTMA #2 Disclosed balance after: 0 Underlying: Common Stock · 1,111 shares Expires 2021-06-03 F6 · derivative.underlying_shares: Previous filings mistakenly reflected this amount as 1,112 shares; the correct amount after appropriate rounding adjustments is 1,111 shares, as reflected above. Read SEC document |
| May 24, 2021 Filed May 25, 2021 19:40 UTC | NEPHROS INC NEPH · Entity 7279 | OtherCommon Stock Warrants (Right to Buy) · Derivative | 1,111 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0000914190-21-000162 · edgar.xml · derivative · entry 11 Evans Daron · CIK 0001411726 · CEO of Specialty Renal Product 10b5-1 filing: Not disclosed Ownership: Indirect · By UTMA #1 Disclosed balance after: 0 Underlying: Common Stock · 1,111 shares Expires 2021-06-03 F6 · derivative.underlying_shares: Previous filings mistakenly reflected this amount as 1,112 shares; the correct amount after appropriate rounding adjustments is 1,111 shares, as reflected above. Read SEC document |
| May 24, 2021 Filed May 25, 2021 19:40 UTC | NEPHROS INC NEPH · Entity 7279 | OtherCommon Stock | 1,111 | $2.70 | $2,999.70 |
DisclosureSEC source: 0000914190-21-000162 · edgar.xml · nonDerivative · entry 3 Evans Daron · CIK 0001411726 · CEO of Specialty Renal Product 10b5-1 filing: Not disclosed Ownership: Indirect · By UTMA #2 Disclosed balance after: 9,018 Read SEC document |
| May 24, 2021 Filed May 25, 2021 19:40 UTC | NEPHROS INC NEPH · Entity 7279 | OtherCommon Stock | 1,111 | $2.70 | $2,999.70 |
DisclosureSEC source: 0000914190-21-000162 · edgar.xml · nonDerivative · entry 2 Evans Daron · CIK 0001411726 · CEO of Specialty Renal Product 10b5-1 filing: Not disclosed Ownership: Indirect · By UTMA #1 Disclosed balance after: 9,296 Read SEC document |
| March 12, 2020 Filed Mar 12, 2020 21:02 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 2,500 | $6.65 | $16,625.00 |
DisclosureSEC source: 0000914190-20-000113 · edgar.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,215 Read SEC document |
| March 05, 2020 Filed Mar 5, 2020 22:18 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 2,500 | $8.44 | $21,109.00 |
DisclosureSEC source: 0000914190-20-000107 · edgar.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,715 F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.40 to $8.4567. The reporting person undertakes to provide Nephros, Inc., any security holder of Nephros, Inc. or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2020 Filed Feb 5, 2020 22:13 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (Right to Buy) · Derivative | 97,076 | $0.00 Strike: $5.40 | $0.00 |
DisclosureSEC source: 0000914190-20-000041 · edgar.xml · derivative · entry 8 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,690 Underlying: Common Stock · 97,076 shares Expires 2025-04-15 F3 · derivative.exercise_date: On 4/15/15, the Reporting Person was granted an option to purchase up to 242,690 shares of common stock of the Company. Options to purchase 84,941 shares vest quarterly in 16 equal amounts commencing on 6/30/15; options to purchase 36,404 shares vested upon the approval of the listing of the Company's common stock on the Nasdaq Stock Market; and options to purchase 121,345 shares will vest, if ever, upon the Company's achievement of certain annual revenue milestones as specified in that certain Employment Agreement dated 4/15/15 between the Reporting Person and the Company. The Company achieved the $3,000,000 annual revenue milestone in fiscal year 2017 and options to purchase 24,269 shares vested on 2/1/18. The Company achieved both the $6,000,000 and $10,000,000 annual revenue milestones in fiscal year 2019 and 97,076 shares vested on 2/1/20. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 22:14 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $8.57 | $0.00 |
DisclosureSEC source: 0000914190-19-000509 · edgar.xml · derivative · entry 10 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-12-16 F6 · derivative.exercise_date: On 12/16/19, the Reporting Person was granted an option to purchase 20,000 shares of common stock of the Company. Options to purchase 5,000 shares vest on 12/16/20 and options to purchase 15,000 shares vest quarterly in 12 equal amounts commencing on 3/16/21. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 22:14 UTC | NEPHROS INC NEPH · Entity 7279 | GrantCommon Stock | 9,282 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-19-000509 · edgar.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,215 F1 · shares: On December 16, 2019, the Company granted 9,282 shares of restricted stock (the "Restricted Stock") to the Reporting Person in lieu of a cash bonus. The Restricted Stock was granted under the Company's 2015 Equity Incentive Plan. The Restricted Stock vests six months following the grant date. Read SEC document |
| November 18, 2019 Filed Nov 18, 2019 17:12 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 1,000 | $8.35 | $8,350.00 |
DisclosureSEC source: 0000914190-19-000416 · edgar.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,933 Read SEC document |
| August 22, 2019 Filed Aug 22, 2019 20:09 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 2,000 | $6.92 | $13,845.40 |
DisclosureSEC source: 0000914190-19-000336 · edgar.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,933 Read SEC document |
| August 09, 2019 Filed Aug 13, 2019 22:09 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (Right to Buy) · Derivative | 36,404 | $0.00 Strike: $5.40 | $0.00 |
DisclosureSEC source: 0000914190-19-000294 · edgar.xml · derivative · entry 8 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,614 Underlying: Common Stock · 36,404 shares Expires 2025-04-15 F3 · derivative.exercise_date: On 4/15/15, the Reporting Person was granted an option to purchase up to 242,690 shares of common stock of the Company. Options to purchase 84,941 shares vest quarterly in 16 equal amounts commencing on 6/30/15; options to purchase 36,404 shares vested upon the approval of the listing of the Company's common stock on the Nasdaq Stock Market; and options to purchase 121,345 shares will vest, if ever, upon the Company's achievement of certain annual revenue milestones as specified in that certain Employment Agreement dated 4/15/15 between the Reporting Person and the Company. The Company achieved the $3,000,000 annual revenue milestone in fiscal year 2017 and options to purchase 24,269 shares vested on 2/1/18. Read SEC document |
| June 14, 2019 Filed Jun 14, 2019 16:34 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 8,000 | $0.60 | $4,829.60 |
DisclosureSEC source: 0000914190-19-000212 · edgar.xml · nonDerivative · entry 5 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By UTMA #4 Disclosed balance after: 8,000 F6 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.5925 to $0.6085. The reporting person undertakes to provide Nephros, Inc., any security holder of Nephros, Inc. or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 14, 2019 Filed Jun 14, 2019 16:34 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 8,000 | $0.61 | $4,875.20 |
DisclosureSEC source: 0000914190-19-000212 · edgar.xml · nonDerivative · entry 4 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By UTMA #3 Disclosed balance after: 8,000 F5 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.605 to $0.61. The reporting person undertakes to provide Nephros, Inc., any security holder of Nephros, Inc. or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 14, 2019 Filed Jun 14, 2019 16:34 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 8,000 | $0.59 | $4,720.00 |
DisclosureSEC source: 0000914190-19-000212 · edgar.xml · nonDerivative · entry 3 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By UTMA #2 Disclosed balance after: 71,166 Read SEC document |
| June 14, 2019 Filed Jun 14, 2019 16:34 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 8,000 | $0.58 | $4,652.80 |
DisclosureSEC source: 0000914190-19-000212 · edgar.xml · nonDerivative · entry 2 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By UTMA #1 Disclosed balance after: 73,666 F4 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.521 to $0.59. The reporting person undertakes to provide Nephros, Inc., any security holder of Nephros, Inc. or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 14, 2019 Filed Jun 14, 2019 16:34 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 11,172 | $0.60 | $6,683.09 |
DisclosureSEC source: 0000914190-19-000212 · edgar.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,052,426 F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.59 to $0.60. The reporting person undertakes to provide Nephros, Inc., any security holder of Nephros, Inc. or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 108,296 shares of restricted stock that vest on 6/14/19. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 22:34 UTC | NEPHROS INC NEPH · Entity 7279 | GrantCommon Stock | 108,296 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-18-000571 · edgar.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,001,254 F1 · shares: On December 14, 2018, the Company granted 108,296 shares of restricted stock (the "Restricted Stock") to the Reporting Person in lieu of a cash bonus. The Restricted Stock was granted under the Company's 2015 Equity Incentive Plan. The Restricted Stock vests six months following the grant date. Read SEC document |
| May 14, 2018 Filed May 14, 2018 11:27 UTC | NEPHROS INC NEPH · Entity 7279 | OtherCommon Stock Warrants (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0000914190-18-000195 · edgar.xml · derivative · entry 8 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By PoC Capital, LLC Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2021-06-03 F2 · ownership.nature: The Reporting Person is a managing director of the LLC that owns the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.